This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • How we will treat chronic myeloid leukaemia in 201...
Journal

How we will treat chronic myeloid leukaemia in 2016.

Read time: 1 mins
Published:25th Mar 2020
Author: Talati C, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M.
Source: Blood Reviews
Ref.:Blood Rev. 2015;29:137-42
DOI:10.1016/j.blre.2014.12.003

Imatinib will become generic in 2016; assuming that its price will decrease precipitously, we expect that the economic forces will change our current practice habits. We reviewed the literature on the current recommendations to treat chronic myeloid leukemia and highlight how we plan to deal with these changes. Specifically, we propose to better characterize patients according to prognostic scores, to allow more attention to those at high risk for disease progression, e.g., 3-month guidelines and BCR/ABL1 message half-time, emphasize compliance by using contemporary technologies, and increase the importance of early monitoring. We hope that our message will open communication between providers, insurance companies and healthcare authorities to offer the best care for our patients.

Read abstract on library site